Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

NEW YORK, May 26, 2026 — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new AUVELITY® data in major depressive disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting being held from May 26-29 in Miami, FL.

Details of the presentations are as follows:

• Title: Effects of Dextromethorphan-Bupropion (45 mg/105 mg) in Participants with Major Depressive Disorder and Anxious Distress Presentation Date and Time: Wednesday, May 27, 11:45 a.m. - 1:30 p.m. ET Lead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH Poster Number: W42
• Title: Anxiolytic Effects of Dextromethorphan-Bupropion (45 mg/105 mg): Post Hoc Analyses Across Trials in Major Depressive Disorder Presentation Date and Time: Wednesday, May 27, 11:45 a.m. - 1:30 p.m. ET Lead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH Poster Number: W50
• Title: Real-World Clinical Outcomes of Patients Switching to Treatment with Dextromethorphan-Bupropion (45 mg/105 mg) Presentation Date and Time: Thursday, May 28, 11:45 a.m. - 1:15 p.m. ET Lead Author: Joel L. Young, MD, Medical Director of the Rochester Center for Behavioral Medicine, NY Poster Number: T34
• Title: Effects of Solriamfetol on Neuropsychological Outcomes in Patients with Obstructive Sleep Apnea in the Real-World SURWEY Study Presentation Date and Time: Thursday, May 28, 11:30 a.m. - 1:15 p.m. ET Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany Poster Number: T29

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.